What we're reading, February 9, 2016: Novartis signs 2 performance-based deals for its new heart drug; 8 states significantly reduced uninsured rates; and the Obama administration will ask for $1.8 billion to prepare to fight the Zika virus.
Novartis has made deals with Cigna and Aetna for performance-based pricing for the new heart drug Entresto. The agreement would link payments to Novartis to how well the drug improves the relative health of customers based on a reduction in the proportion of customers admitted to the hospital for heart failure, according to Reuters. Aetna’s agreement is based on the drug replicating the results achieved during clinical trials: reducing hospitalizations and the rate of cardiovascular death related to heart failure.
In 8 states, the rate of uninsured residents dropped significantly last year, according to a report from the government. The states—Arizona, California, Colorado, Florida, Illinois, Kentucky, Michigan, and New York—represent a mix of red and blue and 5 have Republican governors, reported AP. Another 10 states reported notable reductions, although were not categorized by the survey as statistically significant. Those states were Georgie, Idaho, Indiana, Louisiana, Mississippi, New Hampshire, New Mexico, North Carolina, Oklahoma, and Rhode Island.
As Zika virus panic spreads in the US, the CDC is now on the highest level of alert and President Obama will ask Congress for $1.8 billion to help fight the virus. Although, the US has not yet seen a case of Zika transmitted directly in the continental US, with spring, along with an increase in mosquitos, approaching the administration said it wants to be prepared, according to The Washington Post. In Atlanta, more than 300 CDC staff are working to monitor and coordinate the Zika response. However, Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases, said he does not expect a major outbreak in the US.
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
Real-World Study Reveals Key Insights Into DLBCL Treatment Patterns, Outcomes
April 18th 2024A recent study offers valuable insights into the characteristics, treatment patterns, and outcomes of diffuse large B-cell lymphoma (DLBCL) in patients across different lines of therapy, providing a look into the landscape of DLBCL management.
Read More
Drs Raymond Thertulien, Joseph Mikhael on Racial Disparities in Multiple Myeloma Care Access
December 28th 2023In the wake of the 2023 American Society of Hematology Annual Meeting and Exposition, Raymond Thertulien, MD, PhD, of Novant Health, and Joseph Mikhael, MD, MEd, FRCPC, FACP, chief medical officer of the International Myeloma Foundation, discussed health equity research highlights from the meeting and drivers of racial disparities in multiple myeloma outcomes.
Listen
Gene, Light Therapy Combo Shows Promise Against Prostate Cancer Cells in Proof-of-Concept Study
April 18th 2024In their preclinical model, the researchers found efficacy both in vitro and in vivo by using CRISPR-Cas9 to mimic porphyria and combining the technology with light therapy.
Read More
Pegcetacoplan for PNH More Cost-Effective Than Anti-C5 Monoclonal Antibodies
April 18th 2024A cost-utility analysis conducted from the perspective of the Italian health system found that pegcetacoplan was more effective and less costly than 2 complement 5 (C5) inhibitors for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
Read More